C4 Therapeutics (CCCC) Equity Ratio (2019 - 2025)
Historic Equity Ratio for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 0.58.
- C4 Therapeutics' Equity Ratio fell 986.55% to 0.58 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.13, marking a year-over-year decrease of 2081.87%. This contributed to the annual value of 0.62 for FY2024, which is 550.17% down from last year.
- C4 Therapeutics' Equity Ratio amounted to 0.58 in Q3 2025, which was down 986.55% from 0.59 recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' Equity Ratio peaked at 0.79 during Q2 2021, and registered a low of 0.58 during Q3 2025.
- Moreover, its 5-year median value for Equity Ratio was 0.65 (2023), whereas its average is 0.67.
- Per our database at Business Quant, C4 Therapeutics' Equity Ratio skyrocketed by 21537.43% in 2021 and then tumbled by 1267.99% in 2022.
- C4 Therapeutics' Equity Ratio (Quarter) stood at 0.77 in 2021, then fell by 12.68% to 0.67 in 2022, then decreased by 2.61% to 0.65 in 2023, then dropped by 5.5% to 0.62 in 2024, then dropped by 5.86% to 0.58 in 2025.
- Its Equity Ratio stands at 0.58 for Q3 2025, versus 0.59 for Q2 2025 and 0.61 for Q1 2025.